Group 1 - Jichuan Pharmaceutical has acquired exclusive commercialization rights for the drug Benvimod Ointment in mainland China, with a total payment not exceeding RMB 1.9 billion (including tax) [1][7] - Benvimod Ointment is the first approved treatment for eczema in children aged 2 and above in China, providing a non-hormonal option for young patients [1][7] - The product is expected to be launched in November 2024 and is currently in the early stages of market expansion [1][7] Group 2 - BeiGene reported a total revenue of USD 5.3 billion for 2025, a 40% increase year-on-year, with significant contributions from its products [2][8] - The company anticipates revenue of USD 6.2 to 6.4 billion for 2026, with GAAP operating profit projected at USD 7 to 8 billion [2][8] Group 3 - Charles River Laboratories announced the divestiture of its entire CDMO business and part of its early discovery services in Europe, generating approximately USD 2.87 billion in revenue last year [3][9] - The divested CDMO business, which focuses on gene therapy production, is expected to be sold to GI Partners and IQVIA [3][9] Group 4 - Zai Lab reported a total revenue of USD 127.6 million for Q4 2025, a 17% increase year-on-year, and an annual revenue of USD 460.2 million, a 15% increase [4][10] - The company is advancing its pipeline with several promising products expected to enter registration studies by the end of 2026 [4][10] Group 5 - Baillie Gifford's ADC drug, Iza-bren, achieved positive results in a Phase III trial for triple-negative breast cancer, marking a significant milestone for the drug [5][10] - The trial demonstrated a significant extension in both progression-free survival (PFS) and overall survival (OS) [5][10] Group 6 - Tianchen Biopharmaceuticals is preparing for an IPO on the Hong Kong Stock Exchange, having raised significant funding in recent years [6][11] - The company focuses on developing innovative drugs for allergic and autoimmune diseases, with key products currently in clinical development [6][11] Group 7 - Zhixiang Jintai reported a total revenue of approximately RMB 231 million for 2025, a staggering increase of 666.65% year-on-year, despite significant losses [12][13] - The company experienced a decline in operating profit and net profit compared to the previous year [12][13]